Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

NanoViricides, Inc. NNVC

Healthcare  —  Biotechnology
1.44 0.00 0.00% as of 25 Sep
Market cap
$38.0M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

NanoViricides, Inc. (NNVC) Business Profile

Updated before January 2025

Company Overview

NanoViricides, Inc. (NNVC) is a clinical-stage biotechnology company specializing in the development of nanomedicine-based antiviral therapies. Founded in 2005, the company is headquartered in Shelton, Connecticut, USA. NanoViricides was co-founded by Dr. Anil Diwan, who currently serves as the Chairman and President. Dr. Diwan is a pioneer in nanomedicine and holds several patents in the field. The company’s leadership team also includes Eugene Seymour, MD, MPH, as the Chief Executive Officer, and Dr. Mukund Kulkarni as the Chief Regulatory Officer. Together, the leadership team brings decades of experience in biotechnology, pharmaceuticals, and regulatory affairs.

NanoViricides operates with a mission to revolutionize antiviral treatments by leveraging its proprietary nanoviricide platform technology. The company’s innovative approach aims to address unmet medical needs in the treatment of viral infections, including those caused by influenza, herpes, and coronaviruses.

Core Business Segments

NanoViricides focuses on the development of antiviral therapies using its proprietary nanomedicine platform. The company’s core business segments include:

1. Nanoviricide Drug Candidates

NanoViricides develops drug candidates designed to combat specific viral infections. These drug candidates are based on the company’s unique nanoviricide technology, which involves creating virus-binding ligands attached to a nanomicelle platform. Key drug candidates include:

  • NV-HHV-101: A topical treatment for herpes simplex virus infections, including cold sores and genital herpes.
  • FluCide™: A broad-spectrum antiviral targeting various strains of influenza, including drug-resistant variants.
  • COVIDCide™: A potential treatment for COVID-19, targeting SARS-CoV-2 and its variants.
  • HIVCide™: A preclinical candidate aimed at treating HIV/AIDS.

2. Platform Technology Licensing

NanoViricides also offers licensing opportunities for its proprietary nanoviricide platform. This technology can be adapted to target a wide range of viral infections, making it a valuable asset for pharmaceutical companies seeking to develop antiviral therapies.

3. Research and Development Services

The company provides R&D services to advance its drug candidates through preclinical and clinical stages. This includes in-house testing, formulation development, and regulatory compliance support.

Business Model

NanoViricides operates on a research-driven business model focused on innovation and collaboration. The company generates revenue through:

  • Drug Development: Advancing its proprietary drug candidates through clinical trials and eventual commercialization.
  • Licensing Agreements: Partnering with pharmaceutical companies to license its nanoviricide platform for specific applications.
  • Collaborative Research: Engaging in joint research projects with academic institutions and industry partners.

The company’s approach integrates cutting-edge nanotechnology with traditional pharmaceutical development processes. By targeting the virus directly, NanoViricides aims to create therapies that are both effective and less prone to resistance compared to conventional antiviral drugs.

Strategic Direction

NanoViricides is committed to expanding its pipeline of antiviral therapies and advancing its existing drug candidates through clinical trials. Key strategic goals include:

  • Clinical Development: Completing Phase I and Phase II trials for NV-HHV-101 and FluCide™.
  • COVID-19 Focus: Accelerating the development of COVIDCide™ to address the ongoing pandemic and potential future outbreaks.
  • Global Partnerships: Establishing collaborations with pharmaceutical companies and research institutions to enhance R&D capabilities and market reach.
  • Sustainability: Implementing environmentally friendly practices in its manufacturing and R&D processes.
  • New Targets: Exploring applications of its nanoviricide platform for emerging viral threats, such as Zika, Ebola, and Dengue.

Competitive Landscape

NanoViricides operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Gilead Sciences: Known for its antiviral drugs, including treatments for HIV and hepatitis.
  • Moderna: A leader in mRNA-based therapies, including COVID-19 vaccines.
  • Regeneron Pharmaceuticals: Specializes in monoclonal antibody treatments for viral infections.
  • Vir Biotechnology: Focuses on developing innovative therapies for infectious diseases.

NanoViricides differentiates itself through its unique nanoviricide platform, which offers a novel mechanism of action compared to traditional antiviral drugs.

Risk Factors

Like any biotechnology company, NanoViricides faces several risks, including:

  • Regulatory Challenges: Delays or failures in obtaining FDA approval for its drug candidates.
  • Market Dependence: Reliance on the success of a limited number of drug candidates.
  • Supply Chain Disruptions: Potential issues in sourcing raw materials or manufacturing components.
  • Competition: Intense competition from larger pharmaceutical companies with greater resources.
  • Financial Risks: Dependence on external funding and potential dilution of shareholder value.

Recent Developments

NanoViricides has made significant progress in recent years, including:

  • Preclinical Success: Demonstrating efficacy of NV-HHV-101 in animal models for herpes simplex virus.
  • COVID-19 Research: Advancing COVIDCide™ through preclinical studies targeting SARS-CoV-2.
  • Manufacturing Facility: Establishing a state-of-the-art cGMP-compliant manufacturing facility to support clinical trials and future commercialization.
  • Collaborations: Partnering with academic institutions to explore new applications of its nanoviricide platform.

Global events, such as the COVID-19 pandemic, have highlighted the importance of antiviral therapies and increased interest in NanoViricides’ technology.

Investment Considerations

Investors considering NanoViricides should weigh the following factors:

Strengths

  • Innovative Technology: Proprietary nanoviricide platform with broad applications.
  • Strong Pipeline: Multiple drug candidates targeting high-value markets.
  • Experienced Leadership: A team with extensive expertise in biotechnology and pharmaceuticals.

Risks

  • Early-Stage Company: Limited revenue and dependence on external funding.
  • Regulatory Uncertainty: Potential delays in clinical trials and FDA approvals.
  • Market Competition: Intense competition from established players in the antiviral space.

Conclusion

NanoViricides, Inc. is a promising player in the biotechnology sector, leveraging its innovative nanoviricide platform to address unmet medical needs in antiviral therapy. While the company faces challenges typical of early-stage biotech firms, its strong pipeline and experienced leadership position it for future growth. As global demand for effective antiviral treatments continues to rise, NanoViricides is well-positioned to make a significant impact in the healthcare industry.